Allarity Therapeutics (ALLR) Reports Key Progress in Phase 2 Stenoparib Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St futures tepid as Middle East tensions keep investors wary
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Tesla to unveil Cybercab Texas today, details are few
- Snowflake soars 20% on earnings beat and raised guidance
- Oil prices hit fresh 6-week highs on renewed Middle East tensions
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
November 18, 2024 8:00 AM ESTof advanced ovarian cancer
Allarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparibs clinical development toward FDA approval Expansion of Allarity Medical Laboratory into revenue-generating services
for external biotech clients
Continued focus on advancing stenoparib to address
critical unmet needs in ovarian... More
